Gensight Biologics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

03.03.20	GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS (Businesswire)
11.12.19	GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history (Businesswire)
09.12.19	The Quinze-Vingts Hospital and GenSight Biologics Announce a First Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France (Businesswire)
09.10.19	GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapy (Businesswire)
08.10.19	GenSight Biologics Appoints Magali Taiel as Chief Medical Officer (Businesswire)
23.09.19	GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
11.07.19	GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule (Businesswire)
29.05.19	Sustained Bilateral Improvement from GenSight Biologics’ REVERSE Phase III Clinical Trial Represents Transformative Therapeutic Benefit for Patients, Key Opinion Leaders Conclude (Businesswire)
15.05.19	GenSight Biologics Reports Positive 96-Week Data from REVERSE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
06.05.19	GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN) (Businesswire)
25.04.19	GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE & RESCUE Phase III Trials of GS010 at the Annual Meeting of ARVO (Businesswire)
17.04.19	GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical Trial of GS010 in Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
15.03.19	GenSight Biologics Announces Presentation of 72-Week Data From the REVERSE Phase III Trial of GS010 at the 45th Annual Meeting of NANOS (Businesswire)
12.02.19	GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology (Businesswire)
12.12.18	GenSight Biologics Reports Sustained Quality of Life Improvements at Week 72 of Phase III REVERSE Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
26.10.18	GenSight Biologics Enrolls First Subject in First-in-man PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa (Businesswire)
18.10.18	GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
18.10.18	GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
13.09.18	GenSight Biologics Provides an Update on the Clinical and Regulatory Pathways for GS010 (Businesswire)
20.06.18	GenSight Biologics : Key Opinion Leaders Highlight GS010 Efficacy and Patient Benefits in Discussion of Findings from REVERSE Phase III Clinical Trial (Businesswire)
12.06.18	GenSight Biologics Reports Positive Additional Data from REVERSE Phase III Clinical Trial of GS010 for Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
21.05.18	GenSight Biologics to Host KOL Event on June 12, 2018 (Businesswire)
26.04.18	GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO (Businesswire)
03.04.18	GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
28.02.18	GenSight Biologics Reports Full Year 2017 Financial Results (Businesswire)
20.02.18	GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in Ophthalmology, the Journal of the American Academy of Ophthalmology (Businesswire)
25.01.18	GenSight Biologics Reports €55 Million 2017 Year-End Cash Position and Provides Corporate Update (Businesswire)
25.01.18	GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing (Businesswire)
17.01.18	GenSight Biologics Announces Its 2018 Financial Calendar (Businesswire)
10.01.18	GenSight Biologics Receives MHRA Approval to Initiate Phase I/II PIONEER Clinical Trial of GS030 Gene Therapy in Retinitis Pigmentosa (Businesswire)
06.11.17	GenSight Biologics to Participate in Multiple Conferences in November (Businesswire)
26.10.17	GenSight Biologics Reports its Cash Position as of September 30, 2017 (Businesswire)
25.10.17	GenSight Biologics Appoints Barrett Katz as Chief Medical Officer (Businesswire)
16.10.17	GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy (Businesswire)
04.10.17	GenSight Biologics to Attend Chardan Gene Therapy Conference (Businesswire)
02.10.17	GenSight Biologics Integrates the Enternext® PEA-PME 150 Index (Businesswire)
19.09.17	GenSight Biologics Integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext Indexes (Businesswire)
01.08.17	GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the Treatment of Leber’s Hereditary Optic Neuropathy (Businesswire)
28.07.17	GenSight Biologics Reports Interim Financial Results for the First Half of 2017 (Businesswire)
23.06.17	Publication of the Securities Note Having Obtained Visa No. 17-297 of the AMF in Connection with the Capital Increase of GenSight Biologics (Businesswire)
11.05.17	GenSight Biologics: Annual General Meeting on May 31, 2017 (Businesswire)
08.05.17	GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO (Businesswire)
03.05.17	Gensight Biologics Appoints Mohamed Genead as Chief Medical Officer (Businesswire)
26.04.17	GenSight Biologics Reports Its Cash Position as of March 31, 2017 (Businesswire)
19.04.17	GenSight Biologics to Attend Upcoming Investor Conferences (Businesswire)
13.03.17	GenSight Biologics Reports Full Year 2016 Financial Results (Businesswire)
20.12.16	GenSight Biologics Reports Sustained Visual Acuity Gain at 78 Weeks in Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON) (Businesswire)
09.11.16	GenSight Biologics to Present at the Stifel Healthcare Conference on November 15, 2016 in New York (Businesswire)
08.11.16	GenSight Biologics Wins 2016 Deloitte Technology Fast 50 "Biotech of the Future” Award for the Paris Region (Businesswire)
13.10.16	GenSight Biologics Reports Its Cash Position as of September 30, 2016 (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	76.62	0.39 %	K V
Part Grp Hldg	1’271.50	0.36 %	K V
Holcim	89.08	0.25 %	K V
Logitech Intl	74.82	-0.05 %	K V
Lonza Grp	540.60	-0.15 %	K V
UBS Group	27.82	-1.24 %	K V
Sika	223.10	-1.37 %	K V
Nestle	74.10	-1.49 %	K V
Swiss Re	129.60	-1.78 %	K V
Givaudan	3’961.00	-2.46 %	K V